Dr. Ferris on Pembrolizumab and Nivolumab in Head and Neck Cancer
Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses nivolumab (Opdivo) and pembrolizumab (Keytruda) for patients with head and neck cancer.
Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses nivolumab (Opdivo) and pembrolizumab (Keytruda) for patients with head and neck cancer.
The field has gotten to a point where pembrolizumab and nivolumab can be used interchangeably, explains Ferris.
According to Ferris, trials looking at combinations and earlier lines of therapy with chemoradiation are being investigated with both of these agents.
